WALTHAM, Mass., Nov. 22, 2021 (World NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a scientific-phase biopharmaceutical business focused on the discovery, progress and commercialization of antibody-primarily based alternatives for infectious ailments with pandemic likely, now announced that Jill Andersen has been appointed as chief lawful officer, bringing above 20 years of legal, compliance and management working experience in the pharmaceutical sector, govt and non-public practice. In addition, Redonda Miller, M.D., MBA, president of The Johns Hopkins Healthcare facility, and Ellen Marram, an seasoned corporate director and board chief, and the former CEO of many client product providers, have joined Adagio’s board of administrators.
“We are thrilled to develop our government group and welcome Jill as our chief legal officer,” explained Tillman Gerngross, Ph.D., co-founder and main govt officer of Adagio. “The crucial focus at Adagio now is our swift development of ADG20 by means of two world-wide scientific trials toward a opportunity unexpected emergency use authorization and in the long run, a total acceptance, as we operate to fight the ongoing COVID-19 pandemic. Jill has tremendous expertise and a tested keep track of file throughout a selection of authorized capabilities in the pharmaceutical market, such as foremost by a the latest Fda acceptance and solution launch. Her counsel and expertise will be instrumental in our regulatory and company execution heading forward.”
Rene Russo, co-founder and chairman of Adagio’s board of administrators commented, “Adagio’s dedication to advancing a potent and broadly neutralizing therapeutic to deal with the COVID-19 pandemic is unparalleled, and it’s important that we have a robust workforce to information both equally scientific improvement and the anticipated upcoming commercialization. The additions of Redonda and Ellen to the Adagio board complement the company’s experienced and seasoned management team and board. As the chief of one particular of the nation’s top rated hospitals, Redonda supplies a valuable individual point of view and vital insights into the clinical development of compelling medications, specially getting been on the front strains all through the COVID-19 pandemic. Ellen delivers a exclusive viewpoint as a confirmed organization leader who has led a lot of corporations and built dozens of worthwhile customer models, quite a few of which handle purchaser overall health considerations. We appear ahead to partnering with them in an effort to deliver significantly-required prophylactic and therapeutic selections for this ongoing disaster.”
Ms. Jill Andersen
Ms. Andersen joins Adagio from Oyster Level Pharma where she served as basic counsel, corporate secretary and chief compliance officer, and recently led and supported essential parts of the company’s 1st Fda approval and item launch. Prior to that, she was with Bristol Myers Squibb, pursuing the Celgene acquisition, and served as vice president, head of lawful for the swelling & immunology world-wide franchise. Prior to becoming a member of Celgene, she held positions of increasing duty at Novartis, which includes senior leadership roles in lawful and compliance at Novartis Pharmaceuticals Corporation, Novartis Client Overall health and Novartis Companies. Ms. Andersen has worked extensively on issues connected to merchandise advancement, marketing and advertising acceptance and commercialization, which includes solution launches across various therapeutic parts. Her practical experience also spans company governance, securities, corporate transactions, IP, litigation and investigations. Prior to joining the pharmaceutical marketplace, she was an Assistant U.S. Legal professional for the District of New Jersey and was a litigation associate at the regulation organization of Davis Polk & Wardwell. She holds a J.D. from Wake Forest University, College of Legislation and a B.S. in finance from Boston Faculty.
Dr. Redonda Miller
Dr. Miller has served as the president of The Johns Hopkins Clinic considering the fact that 2016 and has sophisticated the hospital’s focus on delivering outstanding scientific care, boosting high-quality, security and the affected person experience, and strengthening wellness fairness and results for inhabitants in Baltimore Town. All through her tenure, The Johns Hopkins Medical center has constantly been acknowledged for incredible treatment, retaining its rank between the prime hospitals in the nation on the U.S. News & World Report Honor Roll and earning its fourth consecutive Magnet designation for nursing excellence. Dr. Miller arrived at Johns Hopkins as a healthcare pupil in 1988 and joined the medical school in 1997. Given that 2004, she has served in quite a few administrative roles of escalating accountability, together with vice chair of medical operations for the Office of Medication, vice president of clinical affairs for The Johns Hopkins Clinic, and senior vice president of health care affairs for the Johns Hopkins Wellness Procedure. In 2020, Dr. Miller was inducted into the Nationwide Academy of Medication and the Maryland Chamber of Commerce Business Corridor of Fame. She holds an M.D. from Johns Hopkins College School of Drugs, an MBA from Johns Hopkins Carey Small business School and a B.S. in biology from The Ohio Point out University.
Ms. Ellen Marram
Ms. Marram lately retired as the direct director for Eli Lilly and Ford Motor Corporation and previously served as the presiding director of The New York Instances. She was the CEO of the Tropicana Beverage Group and the Nabisco Biscuit Corporation and, as a taking care of director or advisor to various personal equity corporations, mainly focused on wellness-connected shopper manufacturers and served on lots of non-public enterprise boards. She is now the chair of Newman’s Individual Inc, the meals business which provides all income to philanthropic will cause and serves as a director of the Newman’s Individual Foundation. She also serves on a number of wellness-similar and other non-profit boards. Ms. Marram hold an MBA from Harvard Business College and a B.A. from Wellesley Faculty in which she serves as a trustee.
ADG20, an investigational monoclonal antibody focusing on the spike protein of SARS-CoV-2 and connected coronaviruses, is advancing by means of global medical trials for the prevention and remedy of COVID-19, the condition prompted by SARS-CoV-2. ADG20 was intended and engineered to have high efficiency and broad neutralization activity in opposition to SARS-CoV-2 and supplemental clade 1 sarbecoviruses by concentrating on a highly conserved epitope in the receptor binding area. ADG20 was even further engineered to provide an extended 50 %-life for sturdy defense. ADG20 has demonstrated potent neutralizing exercise towards the original SARS-CoV-2 virus, all known SARS-CoV-2 variants of problem and supplemental SARS-like viruses in preclinical reports. ADG20 is administered in scientific trials by a solitary intramuscular injection. To date, ADG20 has been properly-tolerated in a Phase 1 trial with no protection indicators recognized via a minimum amount of three months stick to-up throughout all cohorts. ADG20 has not been permitted for use in any nation, and basic safety and efficacy have not but been established.
About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a medical-phase biopharmaceutical corporation targeted on the discovery, development and commercialization of antibody-primarily based remedies for infectious disorders with pandemic potential, which includes COVID-19 and influenza. The company’s portfolio of antibodies has been optimized applying Adimab’s market-main antibody engineering abilities and is built to deliver people and clinicians with the probable for a highly effective mix of efficiency, breadth, strong protection (by means of 50 %-existence extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes many non-competing, broadly neutralizing antibodies with distinctive binding epitopes, led by ADG20. Adagio has secured producing ability for the output of ADG20 with 3rd-get together agreement producers to guidance the completion of medical trials and original business start, guaranteeing the potential for wide accessibility to men and women all-around the planet. For a lot more information and facts, please stop by www.adagiotx.com.
Ahead On the lookout Statements
This push release contains ahead-on the lookout statements inside of the indicating of the Non-public Securities Litigation Reform Act of 1995. Words these as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or equivalent expressions are supposed to determine ahead-on the lookout statements. Forward-hunting statements include things like statements concerning, amid other points, the timing, development and final results of our preclinical experiments and scientific trials of ADG20, which includes the timing of our planned EUA application, initiation and completion of studies or trials and linked preparatory work, the period of time all through which the results of the trials will come to be offered and our study and development programs our capacity to receive and maintain regulatory approvals for, our item candidates our means to identify clients with the diseases handled by our products candidates and to enroll these sufferers in our scientific trials our manufacturing capabilities and technique and our ability to correctly commercialize our merchandise candidates. We might not in fact obtain the designs, intentions or expectations disclosed in our forward-hunting statements and you should really not position undue reliance on our ahead-on the lookout statements. These forward-seeking statements entail pitfalls and uncertainties that could induce our true effects to differ materially from the success described in or implied by the forward-looking statements, which include, devoid of limitation, those challenges described under the heading “Risk Factors” in Adagio’s Quarterly Report on Kind 10-Q for the quarter finished September 30, 2021 and in Adagio’s foreseeable future reports to be filed with the SEC. These risks may possibly be amplified by the impacts of the COVID-19 pandemic. Forward-seeking statements contained in this press launch are created as of this date, and Adagio undertakes no responsibility to update such details other than as required less than relevant legislation.
Dan Budwick, 1AB
Trader Make contact with:
Monique Allaire, THRUST Strategic Communications